key: cord-0995382-af11ljjl authors: Verhasselt, Hedda L.; Buer, Jan; Dedy, Jutta; Ziegler, Renate; Steinmann, Joerg; Herbstreit, Frank; Brenner, Thorsten; Rath, Peter-Michael title: COVID-19 Co-infection with Legionella pneumophila in 2 Tertiary-Care Hospitals, Germany date: 2021-05-03 journal: Emerg Infect Dis DOI: 10.3201/eid2705.203388 sha: aa159e3742f60f54976c633f1c009a80277268b7 doc_id: 995382 cord_uid: af11ljjl We describe screening results for detection of co-infections with Legionella pneumophila in patients infected with severe acute respiratory syndrome coronavirus 2. In total, 93 patients were tested; 1 was positive (1.1%) for L. pneumophila serogroup 1. Co-infections with L. pneumophila occur in coronavirus disease patients and should not be missed. European Society of Clinical Microbiology and Infectious Diseases Study Group for Legionella Infections give warning of increased risk for Legionella spp. infections resulting from stagnant or standing water in plumbing systems after the temporary shutdown of buildings and reductions in normal water use (4, 5) . A single person with SARS-CoV-2 revealed L. pneumophila co-infection in the context of travel (6) . This case underlines the importance of making differential diagnoses during the COVID-19 pandemic by diagnostic microbiology to identify other infectious microorganisms causing similar symptoms. In this retrospective analysis, we evaluated the co-occurrence of infections with L. pneumophila in patients infected with SARS-CoV-2. We performed urine antigen tests for detection of L. pneumophila serogroup 1 (BinaxNOW Legionella; Abbott Rapid Diagnostics Germany GmbH, https://www.de.abbott). We analyzed urine samples from 93 patients from 2 tertiarycare hospitals in Germany: University Hospital Essen, Essen, and General Hospital Nürnberg, Nuremberg. This retrospective study was approved by the Ethics Committee of the Medical Faculty at the University of Duisburg-Essen, Germany (approval no. 20-9335-BO). The cohort was mostly male (71.0%) and had a mean age of 65 years; 90% had symptoms of pneumonia (Table) . All were hospitalized, and 38.7% received mechanical ventilation. More than one third of the cohort had >2 underlying conditions and reflected the groups at risk for infection with Legionella spp. We detected 1 L. pneumophila serogroup 1 antigen in the entire cohort (1.1%). The patient with L. pneumophila serogroup 1 co-infection was a 41-year-old man with severe acute respiratory deficiency syndrome and bronchial asthma as underlying disease; he initially came to the hospital with fever, cough, and dyspnea and had no recent travel history. Before admission to the University Hospital, he was treated with azithromycin and ceftriaxone for 4 days, until a switch to levofloxacin on day 1 after first diagnosis of LD in the referral hospital. In the University Hospital, urine antigen test was still positive, and detection of Legionella spp. DNA from bronchoalveolar fluid revealed a PCR cycle threshold value of 34 (ampliCube Respiratory Panel 1; Mikrogen Diagnostic, https:// www.mikrogen.de), which was assessed as negative. To exclude a false-positive antigen test result, we retested this specific urine sample after boiling for 5 min and centrifugation (5 min at 12,000 × g), which yielded a positive result again (7) . As of July 2020, the patient was still critically ill, receiving mechanical ventilation and intravenous levofloxacin (500 mg 2×/d; day 6 of levofloxacin treatment). ). However, cross-reactivity of indirect immunofluorescence tests with other bacterial species has been described. Antibody titers without follow-up should be interpreted with caution because antibodies can be generated even after mild infections and can persist over years. In view of epidemiologic data, detection of only L. pneumophila serogroup 1 antigen in urine is a suitable diagnostic approach for outpatient-acquired and travel-associated pneumonia, with varying sensitivity and specificity (8) . The false-negative rate of this diagnostic approach is low because antigen excretion starts 24 hours after first symptoms and generally persists for weeks, and in rare cases even months (9); positive urine antigen tests can be found after initiation of antimicrobial drug treatment. However, pretest probability of L. pneumophila pneumonia should be reasonably high to have clinical utility (10) . The findings from our small cohort study in 2 geographically distinct areas in Germany indicate that co-infections with L. pneumophila serogroup 1 can occur in patients with COVID-19. Clinicians treating patients positive for SARS-CoV-2 should be aware of possible co-infections with L. pneumophila and should use appropriate diagnostic approaches. Dr. Verhasselt is a research associate and laboratory head of the serology section of the Institute of Medical Microbiology at University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Her primary research interests are diagnosis and therapy of fungal infections and antifungal susceptibility testing. China Medical Treatment Expert Group for Covid-19 Community-acquired Legionnaires' disease Legionella and Legionnaires' disease: 25 years of investigation Guidance for reopening buildings after prolonged shutdown or reduced operation ESCMID Study Group for Legionella Infections. ESGLI Guidance for managing Legionella in building water systems during the COVID-19 pandemic SARS-CoV-2 and legionella co-infection in a person returning from a Nile cruise Legionnaires' disease pseudoepidemic due to falsely positive urine antigen test results Diagnostic testing for Legionnaires' disease Onset and duration of urinary antigen excretion in Legionnaires disease Clinical utility of a Legionella pneumophila urinary antigen test in a large university teaching hospital (1) and accounts for a substantial burden among older adults (2) . Although it is generally accepted that RSV epidemics in temperate climates occur in winter, some temporal variation epidemics remains unexplained (3) .Recently, Yu et al. conducted a study among children (<13 years of age) with pneumonia at the Beijing Children's Hospital (Beijing, China) during July 2007-June 2015 and reported that temporal variation is partly explained by seasonal differences in virus subtype dominance (4) . To define the timing of RSV seasonality, they used a regression model and 10% threshold method previously described (3). They found that onset and peak of seasons occurred ≈3-5 weeks earlier and that duration was ≈6 weeks longer when RSV subtype A (RSV-A) was dominant than when subtype B (RSV-B) was dominant. These results, if generalizable, would have major implications for the Temporal variation of respiratory syncytial virus (RSV) epidemics was recently reported to be determined by the dominant RSV subtype. However, when we repeated the analysis for 4 countries in the Northern and Southern Hemispheres, the dominant subtype did not seem to affect temporal variation of RSV epidemics.